Announcement PDF Enlitic, Inc. 1635 Foxtrail Drive, Suite 111A Loveland, CO 80538 www.enlitic.com 21 September 2026 Completion of Consolidation of Capital Enlitic, Inc. (ASX: ENL) (“Enlitic” or the “Company”) advises that the consolidation / reverse share split of the Company’s issued capital on a ten (10) to one (1) basis (“Reverse Share Split”), as approved by shareholders at the Extraordinary General (Special) Meeting on 29 July 2026, has now been completed. The Company’s post-Reverse Share Split capital structure is as follows: ASX Code Quoted Securities Number ENL CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED 726,798,385 ASX Code Unquoted Securities Number ENLAJ OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 132,473,315 ENLAL WARRANT EXPIRING 04-OCT-2028 EX USD 1.16 10,779 ENLAH WARRANT EXPIRING 13-JUL-2030 EX USD 2.84 5,500 Where the Reverse Share Split resulted in a fraction of a security, any fractional entitlements have been rounded up to the nearest whole number. Holding statements are expected to be despatched to securityholders today, Monday, 21 September 2026, advising them of their holdings on a post-Reverse Share Split basis. Normal trading (on a T+2 settlement basis) is expected to commence tomorrow, Tuesday, 22 September 2026. Refer to the Company’s ASX announcements lodged on Friday, 3 July 2026, Monday, 7 September 2026, Wednesday, 9 September 2026 and the Notice of Extraordinary General (Special) Meeting dated 16 July 2026 for further details regarding the Reverse Share Split. ENDS This announcement was authorised for release by the Board of Enlitic, Inc. Enquiries Enlitic Investor Relations Australia: invest_au@enlitic.com Six Degrees Investor Relations Henry Jordan Henry.jordan@sdir.com.au +61 431 271 538 About Enlitic Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, Xray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com. Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.